Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Aetna $77 billion acquisition by CVS Health
Davis Polk is advising Aetna on its approximately $77 billion acquisition by CVS Health. The transaction, which is expected…
Anthem, Inc. Cash Tender Offers
Davis Polk advised the dealer managers in connection with cash tender offers for (i) any and all of Anthem’s 7.000%…
Anthem, Inc. $5.5 Billion Senior Notes Offering
Davis Polk advised the representatives of the several underwriters on an SEC-registered offering by Anthem, Inc. of $5…
Alnylam Pharmaceuticals, Inc. $805 Million Common Stock Offering
Davis Polk advised the underwriters of an $805 million SEC-registered offering of 6,440,000 shares of common stock of…
Davis Polk Advises Roche on Its €250 Million Cash Tender Offer
Davis Polk advised Roche Holdings, Inc. as to U.S. law in connection with its cash tender offer for up to €250 million…
Davis Polk Advises InflaRx N.V. on Its Initial Public Offering
Davis Polk advised InflaRx N.V. on its $100 million initial public offering of 6,667,000 of its common shares. In addition,…
Insulet Corporation Convertible Senior Notes Offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Insulet Corporation of $402.5…
Celgene $3 Billion Notes Offering
Davis Polk advised the joint book-running managers on an SEC-registered offering by Celgene Corporation of $750 million…
Davis Polk Advises McKesson Corporation on Its Acquisition of RxCrossroads from CVS Health Corporation
Davis Polk is advising McKesson Corporation on its acquisition of RxCrossroads, a provider of tailored services to…
Allena Pharmaceuticals Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 5,333,333 shares of common stock of…